Naturalistic Safety Registry Of Celecoxib (CELEBREX(R)) And NSAIDs In Juvenile Idiopathic Arthritis
Status:
Terminated
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
This multi-center observational Registry will collect long-term safety data on patients
treated with celecoxib or non-selective nonsteroidal anti-inflammatory drugs (nsNSAIDs) as
used in clinical practice for the treatment of Juvenile Idiopathic Arthritis (JIA).
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.